Equity Details
Price & Market Data
Price: $3.65
Daily Change: +$0.78 / 21.37%
Daily Range: $3.07 - $5.60
Market Cap: $19,882,824
Daily Volume: 40,338,052
Performance Metrics
1 Week: 234.6%
1 Month: 144.7%
3 Months: 147.8%
6 Months: -47.81%
1 Year: -57.48%
YTD: -53.94%
About MetaVia Inc. (MTVA)
Understand the current valuation of MetaVia Inc. (MTVA). Trading at 3.65, the stock has observed a daily change of +$0.78 / 21.37%. A robust market capitalization of 19,882,824 underscores its market presence. Key performance indicators include YTD (-53.94%) and 1-year (-57.48%) returns.
Company Details
Employees: 8
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
